Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00104741
First received: March 3, 2005
Last updated: February 18, 2011
Last verified: April 2008
  Purpose

RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving triptorelin and flutamide together with radiation therapy may be an effective treatment for prostate cancer. It is not yet known whether giving triptorelin and flutamide together with external-beam radiation therapy is more effective than external-beam radiation therapy alone in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying triptorelin, flutamide, and external-beam radiation therapy to see how well they work compared to external-beam radiation therapy alone in treating patients with stage II or stage III prostate cancer.


Condition Intervention Phase
Prostate Cancer
Drug: flutamide
Drug: triptorelin
Procedure: neoadjuvant therapy
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Impact of complete androgen blockade for 4 months [ Designated as safety issue: No ]
  • Survival, in terms of clinical or biological remission, at 5 years [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Acute and late toxicity [ Designated as safety issue: Yes ]
  • Quality of life [ Designated as safety issue: No ]
  • Value and time-delay to obtain prostate-specific antigen nadir (for patients undergoing external beam radiotherapy alone) [ Designated as safety issue: No ]

Estimated Enrollment: 450
Study Start Date: July 2004
Detailed Description:

OBJECTIVES:

  • Compare the impact of neoadjuvant androgen blockade therapy comprising triptorelin and flutamide followed by conformal external beam radiotherapy and continued androgen blockage therapy vs conformal external beam radiotherapy alone in patients with stage II or III prostate cancer.
  • Compare the survival rate, in terms of 5-year clinical or biological remission, in patients treated with these regimens.
  • Compare overall survival in patients treated with these regimens.
  • Compare acute and late toxicity of these regimens in these patients.
  • Compare quality of life of patients treated with these regimens.
  • Determine the value and time-delay to obtain prostate-specific antigen nadir in patients treated with external beam radiotherapy alone.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo conformal external beam radiotherapy.
  • Arm II: Patients receive androgen blockade therapy comprising triptorelin subcutaneously every 4 weeks and oral flutamide once daily. Androgen blockade therapy continues for a total of 4 months. Two months after initiation of androgen blockade therapy, patients undergo conformal external beam radiotherapy.

Quality of life is assessed.

PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   up to 74 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed prostate cancer, meeting the following clinical staging criteria:

    • Stage T1b-T1c AND prostate specific antigen (PSA) ≥ 10 ng/mL OR Stage T1b-T1c AND Gleason score ≥ 7 OR Stage T2a-T3a
    • No lymph node invasion (N0 or N-)

      • Patients with ≥ 10% risk by the Partin table must undergo curage
    • No metastatic disease (M0) by thoracic radiography and bone scan
  • PSA < 30 ng/mL
  • No history of invasive cancer

PATIENT CHARACTERISTICS:

Age

  • Under 75

Performance status

  • ECOG 0-1

Life expectancy

  • At least 10 years

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • No prior hormonal therapy

Radiotherapy

  • No prior pelvic radiotherapy

Surgery

  • No prior radical prostatectomy
  • No prior castration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00104741

Locations
France
Clinique De Rochebelle Recruiting
Ales, France, F-30100
Contact: Jacques Cretin    33-4-6654-2110      
Institut Sainte Catherine Recruiting
Avignon, France, 84082
Contact: Bruno Chauvet, MD    33-4-9027-6182      
Hopital Louis Pasteur Recruiting
Colmar, France, 68024
Contact: Contact Person    33-03-89-12-4102      
Hopitaux Civils de Colmar Recruiting
Colmar, France, 68024
Contact: Contact Person    33-3-8912-4000      
Centre Hospitalier Universitaire Henri Mondor Recruiting
Creteil, France, 94000
Contact: Jean-Leon Lagrange, MD    33-1-49-814-524    jean-leon.lagrange@hmn.aphp.fr   
Hopital Intercommunal De Creteil Recruiting
Creteil, France, 94010
Contact: Michel Martin, MD    33-1-45-17-52-10    michel.martin@chicreteil.fr   
Hopital Jean Monnet Recruiting
Epinal, France, 88021
Contact: Michel Aubertel    33-3-2968-7020      
Centre Hospitalier Intercommunal des Alpes du Sud Recruiting
Gap, France, 05007
Contact: Abdellatif Zribi, MD    33-4-9240-6785      
Centre Oscar Lambret Recruiting
Lille, France, 59020
Contact: Eric Lartigau, MD, PhD    33-3-2029-5911    e-lartigau@o-lambret.fr   
Centre Hospital Regional Universitaire de Limoges Recruiting
Limoges, France, 87042
Contact: Pierre Clavere, MD    33-5-5505-6268    pierre.clavere@chu-limoges.fr   
Centre Leon Berard Recruiting
Lyon, France, 69373
Contact: Pascal Pommier, MD    33-4-7878-2648    pommier@lyon.fnclcc.fr   
CHU de la Timone Recruiting
Marseille, France, 13385
Contact: Contact person    33-91-385-708      
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes Recruiting
Marseille, France, 13273
Contact: Contact Person    33-91-22-37-00      
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Recruiting
Montpellier, France, 34298
Contact: Jean-Bernard Dubois, MD    33-4-6761-3100      
Centre Hospitalier de Mulhouse Recruiting
Mulhouse, France, 68051
Contact: Contact Person    33-3-8964-7522      
Centre Hospitalier Recruiting
Mulhouse, France, 68070
Contact: Alain Grandgirard    33-3-8964-7522      
Centre Regional Rene Gauducheau Recruiting
Nantes, France, 44035
Contact: Sylvain Bourdin, MD    33-2-4067-9900      
Centre Antoine Lacassagne Recruiting
Nice, France, 06088
Contact: J. M. Hannoun-Levi, MD    33-4-9203-1260      
Clinique De Valdegour Recruiting
Nimes, France, 30900
Contact: Jacques Cretin, MD    33-46-662-58-02      
CHU Pitie-Salpetriere Recruiting
Paris, France, 75651
Contact: Jean-Marc Simon    33-142-178-174      
Hopital d'Instruction des Armees du Val de Grace Recruiting
Paris, France, 75005
Contact: Maryse Fayolle-Campana    33-1-4051-4558      
Hopital Saint-Louis Recruiting
Paris, France, 75475
Contact: Christophe Hennequin, PhD    33-1-4249-4949    christophe.hennequin@sls.ap-hop-paris.fr   
Hopital Tenon Recruiting
Paris, France, 75970
Contact: Francoise Pene, MD    33-1-5601-6562    francoisepene@tnn.aphp.paris.fr   
Centre Hospitalier Lyon Sud Recruiting
Pierre Benite, France, 69495
Contact: Contact Person    33-4-78-86-11-58      
CHU Poitiers Recruiting
Poitiers, France, 86021
Contact: Contact Person    33-549-444-538      
Institut Jean Godinot Recruiting
Reims, France, 51056
Contact: Tan Dat Nguyen, MD    33-03-2650-4351    tandat.nguyen@reims.fnclcc.fr   
Centre Eugene Marquis Recruiting
Rennes, France, 35064
Contact: Elizabeth Le Prise, MD    33-2-9925-3000    elptrennes@fnclcc.fr   
Centre Henri Becquerel Recruiting
Rouen, France, 76000
Contact: Bernard M. Dubray, MD, PhD    33-232-082-262      
Institut Claudius Regaud Recruiting
Toulouse, France, 31052
Contact: Jean-Marc Bachaud, MD    33-5-6142-4242      
Centre Hospitalier Universitaire Bretonneau de Tours Recruiting
Tours, France, 37044
Contact: Olivier Le Floch, MD    33-2-4747-4776    lefloch@med.univ-tours.fr   
Centre Alexis Vautrin Recruiting
Vandoeuvre-les-Nancy, France, 54511
Contact: Contact Person    33-3-8359-8400      
Sponsors and Collaborators
UNICANCER
Investigators
Study Chair: Bernard M. Dubray, MD, PhD Centre Henri Becquerel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00104741     History of Changes
Other Study ID Numbers: CDR0000416088, FRE-FNCLCC-GETUG-14/0207, EU-20503
Study First Received: March 3, 2005
Last Updated: February 18, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage IIB prostate cancer
stage IIA prostate cancer
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Flutamide
Triptorelin Pamoate
Androgen Antagonists
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014